Ertz-Archambault N, Keim P, Von Hoff D. Microbiome and pancreatic cancer: A comprehensive topic review of literature. World J Gastroenterol 2017; 23(10): 1899-1908 [PMID: 28348497 DOI: 10.3748/wjg.v23.i10.1899]
Corresponding Author of This Article
Natalie Ertz-Archambault, MD, Department of Internal Medicine, Mayo School of Graduate Medical Education, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85259, United States. ertz.natalie@mayo.edu
Research Domain of This Article
Oncology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 14, 2017; 23(10): 1899-1908 Published online Mar 14, 2017. doi: 10.3748/wjg.v23.i10.1899
Microbiome and pancreatic cancer: A comprehensive topic review of literature
Natalie Ertz-Archambault, Paul Keim, Daniel Von Hoff
Natalie Ertz-Archambault, Department of Internal Medicine, Mayo School of Graduate Medical Education, Mayo Clinic Arizona, Scottsdale, AZ 85259, United States
Paul Keim, Pathogen Genomics Division, Translational Genomics Institute and Regents Northern Arizona University, Flagstaff, AZ 86001, United States
Daniel Von Hoff, Translational Genomics Institute (TGen), Mayo Clinic Arizona, Scottsdale, AZ 85259, United States
Author contributions: Von Hoff D served as principal investigator, project visionary, and reviewed several drafts of this manuscript; Keim P reviewed manuscript drafts and edited each revision; Ertz-Archambault N performed the background literature research and wrote the manuscript.
Conflict-of-interest statement: All the authors declare that they have no competing interests.
Data sharing statement: This manuscript represents comprehensive topic review from published manuscript on topic as indicated in methods section. Prior drafts and PDF versions of articles utilized as referenced in citation section are available with first author on request ertz-archambault.natalie@mayo.edu. No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Natalie Ertz-Archambault, MD, Department of Internal Medicine, Mayo School of Graduate Medical Education, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85259, United States. ertz.natalie@mayo.edu
Telephone: +1-480-3019824 Fax: +1-480-3014171
Received: October 4, 2016 Peer-review started: October 7, 2016 First decision: October 28, 2016 Revised: December 6, 2016 Accepted: December 21, 2016 Article in press: December 21, 2016 Published online: March 14, 2017 Processing time: 160 Days and 16.9 Hours
Core Tip
Core tip: Recent literature reports influences of microbiome alterations contributing to carcinogenesis of pancreatic cancer. The poor prognostics of pancreatic cancer are related to late recognition and treatment resistance, thus warranting investigations for modifiable risk factors, early screening biomarkers, and microenvironment elements that affect outcomes. Learning the role of microbiome in carcinogenesis may lead to identifying reliable, non-invasive screening strategies, and additional modifiable risk factors. Microbiome studies in pancreatic cancer could offer therapeutic targets and an extraordinary opportunity to favorably transform cancer response to existing treatment protocols and improve survival by reduction of cancer-related cachexia by manipulating human gut microbiota.
